The glass half murky might argue the eventing is occurring too fast to suggest a clear cut distinction from what we would expect with just Avastin, meaning both arms might be acting like Avastin. Bad news. But in order to really nail down this issue you would have to know the rate of enrollment, when the 50 % threshold hits? drop out rates? only the company knows. I wonder if Dror will elaborate more at the next earning call?
Other variables the company does not know but can guesstimate .... is the avastin only arm acting as the avasin only arm should act... 8-9 months overall survival ? and how is the VB-111 arm acting? 8-15 months. 8 months it doesn't work versus 15 months fantastic, or something in-between as I suspect.
I'm cautiously optimistic.
You can see the company has a lot riding on this. Binary event. The interim at 40 % of deaths--or more--when 50 % of patients have completed 12 months of potential study time means that beating futility does have added meaning.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM